Results 21 to 30 of about 33,756 (203)

Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial

Frontiers in Immunology, 2022
ObjectiveTo investigate the efficacy and safety of clinical, magnetic resonance imaging (MRI) changes in active ankylosing spondylitis (AS) patients with etanercept and celecoxib alone/combined treatment.MethodsA randomized controlled trial was conducted
Liudan Tu, Minjing Zhao, Xiaohong Wang, Qingcong Kong, Zena Chen, Qiujing Wei, Qiuxia Li, Qinghong Yu, Zhizhong Ye, Shuangyan Cao, Zhimin Lin, Zetao Liao, Qing Lv, Jun Qi, Ou Jin, Yunfeng Pan, Jieruo Gu   +16 more
doaj   +1 more source

Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail [PDF]

, 2015
2015-02Celecoxib is a nonsteroidal anti-inflammatory drug (selective cyclooxygenase-2 inhibitor) that is widely used. The efficacy and safety of celecoxib for treatment of acute postoperative pain were evaluated in Japanese patients. The objective was to
ITO, MASANORI, HANAOKA, AKIO, ISHIGURO, NAOKI, OKADA, TOSHIYUKI   +3 more
core   +1 more source

Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats.

PLoS ONE, 2014
Nonsteroidal anti-inflammatory drugs (NSAIDs) can produce adverse effects by inhibiting prostaglandin (PG) synthesis. A PGE1 analogue, misoprostol, is often utilized to alleviate NSAID-related gastrointestinal side effects. This study examined the effect
Dustin L Cooper, Derek E Murrell, Christopher M Conder, Victoria E Palau, Grace E Campbell, Shaun P Lynch, James W Denham, Angela V Hanley, Kenny W Bullins, Peter C Panus, Krishna Singh, Sam Harirforoosh   +11 more
doaj   +1 more source

Celecoxib concentration predicts decrease in prostaglandin E₂ concentrations in nipple aspirate fluid from high risk women

BMC Cancer, 2008
Background Epidemiologic studies suggest that long term low dose celecoxib use significantly lowers breast cancer risk. We previously demonstrated that 400 mg celecoxib taken twice daily for 2 weeks lowered circulating plasma and breast nipple aspirate ...
Flynn John T, Ruhlen Rachel L, Hewett John E, Qin Wenyi, Sauter Edward R, Rottinghaus George, Chen Yin-Chieh   +6 more
doaj   +1 more source

Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS

Biochemistry Research International, 2017
Objective. To discuss the effects of genistein on the metabolism of celecoxib in vitro and in vivo. Method. In vitro, the effects of genistein on the metabolism of celecoxib were studied using rat and human liver microsomes.
Xiang Zheng, Jian Wen, Teng-hui Liu, Qiu-Geng Ou-yang, Jian-ping Cai, Hong-yu Zhou   +5 more
doaj   +1 more source

Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models

Frontiers in Oncology, 2020
ObjectiveTo investigate the anti-carcinogenic effect of metronomic Celecoxib (i.e., frequent administration in clinically available doses) against hepatocellular carcinoma (HCC) in the perspective of metastasis, spontaneous hepatocarcinogenesis, cancer ...
Chun-Chieh Yeh, Chun-Chieh Yeh, Pei-Ying Liao, Pei-Ying Liao, Sudhir Pandey, Su-Yung Yung, Hsueh-Chou Lai, Hsueh-Chou Lai, Long-Bin Jeng, Long-Bin Jeng, Wei-Chun Chang, Wei-Chun Chang, Wen-Lung Ma, Wen-Lung Ma, Wen-Lung Ma, Wen-Lung Ma   +15 more
doaj   +1 more source

Inhibition of COX-2-Mediated Arachidonic Acid Metabolism by FGF21-PPARα Axis Alleviates Liver Steatosis. [PDF]

MedComm (2020)
Under physiological conditions, the FGF21‐PPARα axis restrains COX‐2 and maintains arachidonic acid (AA) metabolic homeostasis. During steatotic liver disease, ERK1/2 phosphorylation increases alongside adaptive FGF21/PPARα activation, which is insufficient to suppress COX‐2, leading to COX‐driven AA remodeling, PGE2 accumulation, inflammation, and ...
Xu G, Pan T, Wang G, Qiu F, Leng J, Feng Q, Xue Y, Wang Y, Zheng J, Lu H, Han B, Wang S, Du J, Lv J, Wang B, Pan X.   +15 more
europepmc   +2 more sources

Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2

Journal of Experimental & Clinical Cancer Research, 2008
Background The goal of this study was to determine the effects of a selective Cyclooxygenase (COX)-2 inhibitor on the inhibition of tumor growth and pulmonary metastasis in a Lewis Lung Carcinoma (LLC) animal model. Methods For immunoblot analysis of COX-
Han Jae, Oh Young, Park Won, Pyo Hongryull   +3 more
doaj   +1 more source

Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia.

PLoS ONE, 2021
Hyperlipidaemia is a major risk factor for cardiovascular diseases, the leading cause of death globally. Celecoxib attenuated hypercholesterolaemia associated with CCl4-induced hepatic injury in rats without improving liver function in our previous study.
Martins Ekor, Phyllis Elsie Owusu Agyei, Ernest Obese, Robert Peter Biney, Isaac Tabiri Henneh, Meshack Antwi-Adjei, Ewura Seidu Yahaya, Gordon Amoakohene, Patrick Kafui Akakpo   +8 more
doaj   +1 more source

1‐Azabicyclo[1.1.0]butanes (ABBs) on the Map: Mechanistic Pathways for Catalytic Ring Opening and Functionalizations

Angewandte Chemie, EarlyView.
Catalytic strain‐release ring opening and functionalizations of 1‐azabicyclo[1.1.0]butanes (ABBs) represent a promising strategy for accessing diverse azetidine products. These transformations proceed via polar pathways, radical pathways, and hybrid mechanisms that combine both.
James Shao‐Jiun Yang, Hsuan‐Hung Liao   +1 more
wiley   +2 more sources